NEW YORK (GenomeWeb) – Having earlier this month unveiled its plan to merge with hepatitis B therapeutics firm OnCore Biopharma, Tekmira Pharmaceuticals has provided a few details about its drug-development plans going forward in a recent filing with the US Securities and Exchange Commission.

Going forward, Tekmira aims to make its siRNA-based HBV therapy TKM-HBV the foundation of a treatment regimen that will also include one or two other drugs from OnCore's pipeline of preclinical candidates, it said in the SEC filing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.